A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Recruiting · NCT07671339 · Registry updated 2026-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 | 2026-06-26 | NCT07671339 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeOne Medicines | 76 |
| Breakthrough Cancer | 1 |
| Elicio Therapeutics | 2 |
| Lustgarten Foundation | 12 |
| Memorial Sloan Kettering Cancer Center | 753 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | United States | 46 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | United States | 184 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | New York | United States | 47 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | United States | 186 |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) | Rockville Centre | United States | 29 |
| Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) | Commack | United States | 21 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | United States | 166 |